Great news! That checks one item off the list.

I was hoping that this DSMB report would be combined with the SSRA, or that this 7th DSMB report would include a mention of the plan to conduct the SSRA. I see no mention of the SSRA here despite several mentions in the recently posted MD&A. The statement about the current 2400 patients being sufficient to yield 250 MACE events is good to hear and pretty much confirms that enrollment is done. But.....if the SSRA does still happen, then this could change.

Also, I was hoping to see a statement about all patients remaining on drug until end of trial and not stopping at ~2 years of dosing. It would have been nice to read that the longest patient on drug has now been on drug for ~32 months.

Still great news today! No safety issues!

BearDownAZ